Argireline

Last Updated: August 2026

Argireline is the trade name for acetyl hexapeptide-8 (formerly acetyl hexapeptide-3 — both names appear for the identical molecule), a synthetic six-amino-acid peptide developed by Lipotec (now Lubrizol) around 2000 as a topical alternative to injectable neuromodulators. Its sequence is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂. It is a widely used cosmetic ingredient in anti-aging skincare — not an approved drug.

What is Argireline and how does it work?

Argireline reproduces the N-terminal end of SNAP-25 and competes with native SNAP-25 for its place in the SNARE complex — the protein machinery that lets nerve endings release acetylcholine — so a less-efficient complex means reduced neurotransmitter release and gentler contraction of the small facial muscles that etch expression lines. This is why it's nicknamed "topical Botox," though the mechanism differs fundamentally from botulinum toxin, which enzymatically and irreversibly cleaves SNAP-25 after injection for a far stronger, longer effect. Argireline sits in Peptigrity's skin and anti-aging peptides category.

What does the evidence actually show?

Controlled cosmetic studies support a modest anti-wrinkle effect: the original 2002 study (Blanes-Mira et al.) reported wrinkle depth reduced by up to about 30% after 30 days of twice-daily topical use of a 10% preparation of the hexapeptide1 source, and a later randomized, placebo-controlled study in 60 Chinese subjects (Wang et al., 2013; argireline vs placebo, twice daily for four weeks) reported a 48.9% subjective anti-wrinkle response versus 0% for placebo1 source — measurable, but based on subjective evaluation in a small sample — but effects are modest, the peptide penetrates skin poorly, and some visible benefit may come from a formulation's hydration rather than SNAP-25 inhibition. Read the "erases wrinkles" marketing critically. Evidence level: Small cosmetic RCTs / in-vitro; effects modest.

Is Argireline safe, and is it regulated?

Topical Argireline is generally well tolerated at cosmetic concentrations (5–10%), with infrequent mild local irritation, and minimal systemic exposure because it penetrates poorly — it is a cosmetic ingredient rather than an approved drug, so a patch test is sensible and pregnancy/breastfeeding safety data are limited. It is not a substitute for, or equivalent to, injectable neuromodulators.

Why does raw-material verification matter, and how does Peptigrity verify?

Argireline is sold as a raw peptide for formulation as well as in finished products, and identity/purity of the raw material vary between suppliers — HPLC purity and mass-spec identity confirm the vial contains the correct hexapeptide at the labeled amount. Peptigrity collects independent third-party Certificates of Analysis for Argireline from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The trust score weights lab purity and reviews equally (50/50). See how to read lab results. Compare bulk-ingredient vendors against the independent Argireline lab tests on file.

This section is for educational and informational purposes only and does not constitute medical advice. Argireline is not approved by the FDA or equivalent regulators as a drug; it is sold as a cosmetic ingredient and as a research compound. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.